Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,718 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Access and safety of dexamethasone in multiple myeloma patients].
Slimano F, Tournamille JF, Bardin C, Madelaine I, Hulin C, Moreau P, Rioufol C. Slimano F, et al. Among authors: moreau p. Bull Cancer. 2023 Jun;110(6):731-733. doi: 10.1016/j.bulcan.2023.05.001. Epub 2023 May 22. Bull Cancer. 2023. PMID: 37225617 French. No abstract available.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. Among authors: moreau p. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Richardson PG, Facon T, Venner CP, Bahlis NJ, Offner F, White D, Karlin L, Benboubker L, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Villarreal M, Twumasi-Ankrah P, Labotka R, Rifkin RM, Lonial S, Kumar SK, Rajkumar SV, Moreau P. Richardson PG, et al. Among authors: moreau p. EJHaem. 2023 Aug 3;4(4):995-1005. doi: 10.1002/jha2.759. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024593 Free PMC article.
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Kawano Y, et al. Among authors: moreau p. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37479547 Free article. Clinical Trial.
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P. Mateos MV, et al. Among authors: moreau p. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):385-393. doi: 10.1016/j.clml.2023.02.006. Epub 2023 Mar 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36967244 Clinical Trial.
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Spencer A, Moreau P, Mateos MV, Goldschmidt H, Suzuki K, Levin MD, Sonneveld P, Orlowski RZ, Yoon SS, Usmani SZ, Weisel K, Reece D, Ahmadi T, Pei H, Mayo WG, Gai X, Carey J, Bartlett JB, Carson R, Dimopoulos MA. Spencer A, et al. Among authors: moreau p. Blood Adv. 2024 Jan 23;8(2):388-398. doi: 10.1182/bloodadvances.2023010579. Blood Adv. 2024. PMID: 38048391 Free PMC article. Clinical Trial.
High-efficiency base editing in the retina in primates and human tissues.
Muller A, Sullivan J, Schwarzer W, Wang M, Park-Windhol C, Hasler PW, Janeschitz-Kriegl L, Duman M, Klingler B, Matsell J, Hostettler SM, Galliker P, Hou Y, Balmer P, Virág T, Barrera LA, Young L, Xu Q, Magda DP, Kilin F, Khadka A, Moreau PH, Fellmann L, Azoulay T, Quinodoz M, Karademir D, Leppert J, Fratzl A, Kosche G, Sharma R, Montford J, Cattaneo M, Croyal M, Cronin T, Picelli S, Grison A, Cowan CS, Kusnyerik Á, Anders P, Renner M, Nagy ZZ, Szabó A, Bharti K, Rivolta C, Scholl HPN, Bryson D, Ciaramella G, Roska B, György B. Muller A, et al. Among authors: moreau ph. Nat Med. 2025 Jan 8. doi: 10.1038/s41591-024-03422-8. Online ahead of print. Nat Med. 2025. PMID: 39779923
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J, Chateleix C, Moreau S, Karlin L, Jacquet C, Manier S, Hulin C, Decaux O, Richez V, Chalopin T, Mohty M, Orsini-Piocelle F, Caillot D, Sonntag C, Vignon M, Bobin A, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P. Touzeau C, et al. Among authors: moreau p. Br J Haematol. 2025 Jan 5. doi: 10.1111/bjh.19978. Online ahead of print. Br J Haematol. 2025. PMID: 39757748
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis RM, Carson R, Hofmeister CC. Landgren CO, et al. Among authors: moreau p. Blood. 2024 Dec 9:blood.2024025897. doi: 10.1182/blood.2024025897. Online ahead of print. Blood. 2024. PMID: 39652826
1,718 results